Published in Saudi J Gastroenterol on February 05, 2014
Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol (2015) 0.89
Adherence and treatment satisfaction in liver transplant recipients. Saudi J Gastroenterol (2016) 0.78
Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients. Saudi J Gastroenterol (2015) 0.77
Liver transplantation for hepatitis B virus: Decreasing indication and changing trends. World J Gastroenterol (2015) 0.76
Hepatitis B management: it is time to change the strategy. Saudi J Gastroenterol (2014) 0.75
The declining rates of hepatitis B carriage among adolescents and young people in the Eastern region of Saudi Arabia. Saudi Med J (2016) 0.75
Chronic hepatitis B: update 2009. Hepatology (2009) 16.08
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol (2012) 14.55
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat (2004) 13.18
Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med (2004) 10.91
Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med (2002) 10.78
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA (2006) 10.58
Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med (2004) 10.31
EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol (2008) 9.14
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med (2006) 7.35
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology (2006) 6.67
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2006) 5.65
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2004) 5.40
Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control. N Engl J Med (1996) 4.71
Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology (2001) 4.28
Management of hepatitis B: 2000--summary of a workshop. Gastroenterology (2001) 4.17
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med (2003) 4.12
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology (2000) 3.58
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. Infect Control Hosp Epidemiol (2010) 3.44
Management of hepatitis B: summary of a clinical research workshop. Hepatology (2007) 3.40
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 3.33
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med (2008) 3.33
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology (2007) 3.08
Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology (2009) 3.05
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (2010) 3.02
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97
Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis. Clin Gastroenterol Hepatol (2013) 2.73
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother (2004) 2.67
Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology (2010) 2.38
State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases. Proc Natl Acad Sci U S A (1981) 2.37
Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology (1999) 2.36
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32
Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol (2002) 2.30
Hepatitis B e antigen-negative chronic hepatitis B. Hepatology (2001) 2.29
Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol (2009) 2.21
Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int (2008) 2.19
Natural history and prognosis of hepatitis B. Semin Liver Dis (2003) 2.18
Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology (1989) 2.15
Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology (2010) 2.13
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology (2004) 2.01
Predictors of significant fibrosis in chronic hepatitis B patients with low viremia. J Clin Gastroenterol (2014) 1.98
A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med (2005) 1.97
Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology (2006) 1.97
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med (2008) 1.84
Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology (2008) 1.81
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology (2010) 1.79
APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int (2012) 1.79
Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology (2000) 1.78
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology (2003) 1.78
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology (2005) 1.76
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol (2008) 1.65
Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology (2011) 1.63
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology (2002) 1.60
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology (2005) 1.57
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol (2003) 1.53
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology (2004) 1.52
Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology (2003) 1.48
Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants. Clin Infect Dis (2008) 1.47
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology (2010) 1.47
Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology (2005) 1.46
Lamivudine for chronic delta hepatitis. Hepatology (1999) 1.44
Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme. J Infect (1999) 1.43
Recommendations for preventing transmission of human immunodeficiency virus and hepatitis B virus to patients during exposure-prone invasive procedures. MMWR Recomm Rep (1991) 1.41
Prevalence of HBV, HCV, HIV-1, 2 and HTLV-I/II infections among blood donors in a teaching hospital in the Central region of Saudi Arabia. Saudi Med J (2004) 1.39
The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. J Hepatol (2005) 1.38
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis (2004) 1.37
Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology (2002) 1.33
Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol (2010) 1.27
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol (2012) 1.27
Preventing bloodborne pathogen transmission from health-care workers to patients. The CDC perspective. Surg Clin North Am (1995) 1.25
Seroepidemiology of hepatitis B virus infection in Saudi Arabian children: a baseline survey for mass vaccination against hepatitis B. J Infect (1992) 1.23
Transmission of hepatitis B to patients from four infected surgeons without hepatitis B e antigen. N Engl J Med (1997) 1.23
Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis (2006) 1.22
Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. Lancet (1987) 1.20
Hepatitis B genotypes: relation to clinical outcome in patients with chronic hepatitis B in Saudi Arabia. World J Gastroenterol (2006) 1.20
Long-term protection of hepatitis B vaccine 18 years after vaccination. J Infect (2008) 1.18
Prevalence of hepatitis B surface antigen among male Saudi Arabians. J Infect Dis (1982) 1.18
Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology (2003) 1.16
Hepatitis B virus sero-prevalence among pregnant females in Saudi Arabia. Saudi J Gastroenterol (2008) 1.15
Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int (2011) 1.14
Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology (2010) 1.11
Is there a need to include HIV, HBV and HCV viruses in the Saudi premarital screening program on the basis of their prevalence and transmission risk factors? J Epidemiol Community Health (2009) 1.10
Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet (1988) 1.08
Hepatitis B virus infection in 6,130 unvaccinated Korean-Americans surveyed between 1988 and 1990. Am J Gastroenterol (2007) 1.08
Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology (1995) 1.07
Integration of hepatitis B vaccine into the expanded program on immunization: The Saudi Arabian experience. Ann Saudi Med (1993) 1.07
Prevalence of seromarkers of HBV and HCV among blood donors in eastern Saudi Arabia, 1998-2001. Clin Lab Haematol (2004) 1.05
Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat (2009) 1.04
Updated CDC recommendations for the management of hepatitis B virus-infected health-care providers and students. MMWR Recomm Rep (2012) 1.04
Transmission of hepatitis B virus. Semin Liver Dis (1981) 1.04
Prevalence of hepatitis B and C and blood donors. Saudi Med J (2000) 1.03
Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis (2011) 1.03
A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology (1997) 1.02
Hepatitis B virus in Gizan, Saudi Arabia. J Med Virol (1985) 1.01
Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis. Clin Gastroenterol Hepatol (2013) 2.73
SASLT position statement on the direct-acting antiviral agents for the treatment of hepatitis C virus infection. Saudi J Gastroenterol (2015) 1.41
Effect of erythromycin before endoscopy in patients presenting with variceal bleeding: a prospective, randomized, double-blind, placebo-controlled trial. Gastrointest Endosc (2010) 1.10
Early and late outcome of cardiac surgery in patients with liver cirrhosis. Liver Transpl (2007) 1.08
HCV genotypes among 1013 Saudi nationals: a multicenter study. Ann Saudi Med (2013) 0.92
Revising the upper limit of normal for levels of serum alanine aminotransferase in a Middle Eastern population with normal liver histology. Dig Dis Sci (2013) 0.86
Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin. Dig Dis Sci (2011) 0.77
Liver transplantation in patients with hepatocellular carcinoma: a single-center experience. Exp Clin Transplant (2011) 0.77
Invasive mucormycosis in a patient with liver cirrhosis: case report and review of the literature. Hepat Mon (2013) 0.75
Hepatitis C position statement: Taking a stand and standing by it. Saudi J Gastroenterol (2015) 0.75
Organ donor allocation system for liver transplantation in the Kingdom of Saudi Arabia: Call for major revision. Saudi J Gastroenterol (2015) 0.75
Reappraisal of upper age limit for adult living-donor liver transplantation using right lobe grafts: an outcome analysis. Eur J Gastroenterol Hepatol (2015) 0.75
Low Utility of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Detecting Hepatocellular Carcinoma in Patients Before Liver Transplantation. Exp Clin Transplant (2017) 0.75
Effect of Downstaging and Bridging of Hepatocellular Carcinoma on Survival Following Liver Transplant: A Single Center Experience. Exp Clin Transplant (2017) 0.75